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ABSTRACT 
Background: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus tiotropium monotherapy 
in the UK was assessed using a UMEC/VI treatment-specific economic model based on a chronic obstructive pulmo-
nary disease (COPD) disease-progression model.
Methods: The model was implemented as a linked-equation model to estimate COPD progression and associated 
health service costs, and its impact on quality-adjusted life years (QALYs) and survival. Statistical risk equations for 
clinical endpoints and resource use were derived from the ECLIPSE and TORCH studies, respectively. For the selected 
timeframe (1–40 years) and probabilistic analysis, model outputs included disaggregated costs, total costs, exacerba-
tions, life-years and QALYs gained, and incremental cost-effectiveness ratios (ICERs).
Results: Random-effects meta-analysis of tiotropium comparator trials estimated treatment effect of UMEC/VI 
as 92.17 mL (95 % confidence interval: 61.52, 122.82) in forced expiratory volume in 1 s. With this benefit, UMEC/
VI resulted in an estimated annual exacerbation reduction of 0.04 exacerbations/patient and 0.36 life years gained 
compared to tiotropium over patient lifetime. With an additional 0.18 QALYs/patient and an additional lifetime cost of 
£372/patient at price parity, the incremental cost effectiveness ratio (ICER) of UMEC/VI compared to tiotropium was 
£2088/QALY. This ICER increased to £17,541/QALY when price of UMEC/VI was increased to that of indacaterol plus 
tiotropium in separate inhalers. The ICER improved when model duration was reduced from patient lifetime to 1 or 
5 years, or when treatment effect was assumed to last for 12 months following treatment initiation.
Conclusion: UMEC/VI can be considered a cost-effective alternative to tiotropium at a certain price.
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Background
Chronic obstructive pulmonary disease (COPD), a com-
mon preventable and treatable disease, is character-
ised by persistent and progressive airflow limitation. It 
is associated with an increased chronic inflammatory 
response in the lungs to noxious stimuli [1]. It is ranked 
by the World Health Organisation (WHO) as the fourth 
leading cause of death worldwide. In 2011, as estimated 
by the WHO, there were 2.96 million deaths worldwide 
attributed to COPD [2, 3]. According to data from the 
quality and outcomes framework report, the prevalence 
of diagnosed COPD is 1.6 % (estimated 819,524 people) 
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in the United Kingdom; however, an estimated 3 million 
people have COPD [4].
Globally, the economic impact of COPD is reflected in 
the 3.3 % disability-adjusted life years (DALYs) reported 
in the year 2011 by the WHO [5] and the high percentage 
of patients (nearly 40  %) who are forced to discontinue 
work [6]. Early treatment of COPD involves the use of 
long-acting muscarinic antagonists (LAMAs) such as tio-
tropium, glycopyrronium, and aclidinium or long-acting 
β2-agonist (LABA) monotherapy such as formoterol, sal-
meterol, and indacaterol or combination therapy, as nec-
essary. Co-administration of LAMAs and LABAs is more 
effective in managing stable COPD than either drug 
class alone, as studies indicate improved lung function, 
symptoms, and health status with the former [7–9]. The 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines recommend the use of a combina-
tion of long-acting bronchodilators with differing mecha-
nisms of action if monotherapy is insufficient to control 
the symptoms of COPD [1]. A second bronchodilator 
may be considered in moderate COPD to optimise symp-
tom benefit [1, 10] whilst avoiding the risk of side effects 
associated with dose escalation of a single bronchodilator 
[10]. However, combination treatment in separate inhal-
ers may potentially lead to other challenges such as lower 
adherence/persistence and suboptimal outcomes [11, 12].
Umeclidinium bromide-vilanterol (UMEC/VI) is a 
new fixed-dose LAMA/LABA combination (Anoro®) 
indicated as maintenance bronchodilator treatment in 
patients with COPD. It is available at a delivered dose 
of 55/22  µg once daily in a novel dry-powder inhaler 
(Ellipta®). In the European Union, it is approved as main-
tenance bronchodilator treatment to relieve symptoms 
in adult patients with COPD. The safety and efficacy of 
UMEC/VI has been established through a clinical devel-
opment programme enrolling more than 8000 subjects 
with COPD. Three active-comparator phase 3a studies 
(DB2113360, DB2113374, ZEP117115) [13, 14] in this 
programme evaluated the efficacy of UMEC/VI combi-
nation therapy compared with tiotropium. These studies 
have demonstrated that UMEC/VI provides significant 
improvements in lung function compared to tiotropium 
which has gained worldwide acceptance as a first-line, 
once-daily maintenance therapy for patients with COPD 
[1, 15]. UMEC/VI along with other fixed dual broncho-
dilator combinations may present a new class of initial 
maintenance treatments in COPD.
Treatment costs are an important consideration in 
chronic diseases such as COPD. With the increasing 
number of LAMAs and LAMA/LABA combination 
therapies in the market, treatment costs are likely to be a 
major concern to payers. The objective of this study was 
to assess the cost-effectiveness of UMEC/VI compared 
with tiotropium monotherapy from the UK National 
Health Services (NHS) perspective.
Methods
COPD disease‑specific model
The economic model used in this evaluation was adapted 
from a COPD disease model published elsewhere [16]. 
The disease model itself was based on a conceptual model 
of disease progression. This conceptual model provided 
a framework to describe relationships between different 
demographic and clinical parameters, disease progres-
sion, and health outcomes (Fig. 1a) [17]. This association 
was estimated using data from the Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints 
(ECLIPSE) study [18] and the resulting risk equations 
were connected through a model that predicted utility, 
survival, and health-care resource use in future [16, 19] 
(Fig. 1b; Additional file 1).
Model description
Input parameters in the COPD disease model include 
age, gender distribution, body mass index, cardiovascu-
lar and other comorbidities, prior exacerbation history, 
smoking status and health status measured by the SGRQ 
or St George’s Respiratory Questionnaire for COPD 
(SGRQ-C). The model also requires baseline estimates 
for proportions of patients with dyspnoea, cough and 
sputum, exacerbation rate, forced expiratory volume in 
one second (FEV1), and exercise capacity measured by 
the 6-min walk test (6MWT). One or more of these can 
either be input directly in the model or predicted using 
other available parameters [16, 19].
In each model cycle, based on the statistical risk equa-
tions (Additional file 1) and by using the baseline clinical 
and demographic information of the target population, 
the model estimates the number of moderate and severe 
exacerbations, predicted FEV1 in millilitres, the pro-
portion of patients with dyspnoea or cough and spu-
tum symptoms most days per week, 6MWT distance in 
metres, and SGRQ total score (Fig.  1b). These param-
eter estimates then predict SGRQ scores, survival, and 
resource use in that model cycle. All of these parameters 
have been shown to be good predictors of future disease 
progression in COPD and are therefore used as input 
parameters in the subsequent cycles [17]. For each time 
period, the predicted SGRQ scores were transformed to 
the EQ-5D utility based on a published algorithm [20]. 
The risk equations providing annual rates were further 
adjusted to estimate outcomes at specific cycle lengths.
UMEC/VI treatment‑specific economic model
In order to fit this model to UMEC/VI clinical pro-
gramme, a 6-month trial period was added at the start. It 
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was implemented as two 3-month cycles, and 6-monthly 
cycles thereafter for the remainder of the model time-
frame. In the base case, the model time frame was 
assumed to be over the lifetime of the patients. Separate 
scenario analyses were conducted to assess the benefit of 
UMEC/VI over shorter time frames of 1  year (Scenario 
A) and 5 years (Scenario B).
Model inputs
The baseline cohort used in the model represented the 
UMEC/VI phase 3a trial population derived using an 
integrated analysis of four pivotal trials (DB2113360, 
DB2113361, DB2113373, DB2113374) [13, 21, 22]. In 
instances where such information was not available from 
the UMEC/VI clinical programme, baseline estimates 
from ECLIPSE [18] were used.
The treatment effect was expressed as the difference 
in change from baseline in FEV1 at 24  weeks between 
UMEC/VI and tiotropium. FEV1 was selected as it was 
the primary endpoint in UMEC/VI clinical trial pro-
gramme. The treatment effect was estimated by a ran-
dom-effects meta-analysis of tiotropium comparator 
trials from the UMEC/VI phase 3a clinical programme 
(DB2113360, DB2113374, ZEP117115) [13, 14]. Trials 
results demonstrated that UMEC/VI was superior to 
tiotropium on FEV1 indicating that it provides superior 
bronchodilation to tiotropium. The treatment benefit 
of UMEC/VI over tiotropium was assumed for the life-
time of the patient in the base case. A separate scenario 
analysis was conducted (Scenario C) assuming that the 
treatment effect lasts for a period of 12  months from 
treatment initiation, based on the results of UMEC/VI 
safety study (DB2113359) [23].
Costs
The perspective adopted for costs was that of the 
National Health Service (NHS) in England and Wales. 
The reference year used for costs was 2011–2012. Pro-
ductivity losses, although significant, were omitted 
because of this choice of perspective.
Cost of treatment with tiotropium was obtained from 
the British National Formulary (BNF March 2014) and 
was estimated to be £33.50 for a 30-day supply [24]. The 
cost of UMEC/VI was assumed to be equivalent to tiotro-
pium in the base case and was increased to be equivalent 
to the price of indacaterol plus tiotropium in separate 
inhalers (£62.76) in the sensitivity analyses. Resource-
use costs were estimated using NHS reference costs for 
2013–2014 and are displayed in Table 1.
Cost‑effectiveness analyses
The results of the cost-effectiveness analysis are reported 
here in the form of incremental cost per quality-adjusted 
life year (QALY) gained. Costs and outcomes were cal-
culated separately for each treatment alternative over 
the model timeframe and then discounted at 3.5  % per 
annum [25]. Uncertainty around patient level inputs (first 
order) and risk-equation estimates (second order) was 
further explored using probabilistic sensitivity analysis 
with 5000 iterations. The range of values and the distri-
butions used in the probabilistic sensitivity analyses are 
Fig. 1 a Final conceptual model of COPD. b Linked-equations 
disease progression model for COPD. 6MWT 6-min walk test, COPD 
chronic obstructive pulmonary disease, EQ-5D EuroQol 5 dimen-
sion, FEV1 forced expiratory volume in 1 s, FEV1%p forced expiratory 
volume in 1 s percent predicted, HRQoL health-related quality of 
life, QALY quality-adjusted life year, SGRQ St. George’s Respiratory 
Questionnaire. a Adopted from Tabberer et al. [15]. b Adapted from 
Briggs et al. [14]. a Figure represents association between baseline 
covariates, intermediate outcomes (FEV1, symptoms, exacerbations 
and 6MWT) and final outcomes (mortality, HRQoL and costs). Arrows 
represent direction of effect e.g. baseline covariates affect intermedi-
ate outcomes. b Figure represents schema of linked equations model. 
Baseline covariates at t = 0 predict intermediate and final outcomes 
at t = 1 (model cycle = 1). These then become baseline covariates 
t = 1 to predict intermediate and final outcomes at t = 2 (model 
cycle = 2)
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presented in Table 2 for patient level inputs and in Addi-
tional file 1 for risk equation estimates.
Results
Baseline cohort
The baseline demographic and clinical parameters used 
in the model are displayed in Table  2. Cohort charac-
teristics assumed that all patients were symptomatic 
(modified Medical Research Council scale [mMRC] 
score ≥2) and broadly comparable to symptomatic 
patients in the primary care setting in the United King-
dom [26].
UMEC/VI treatment effect
The random-effects meta-analysis of tiotropium compar-
ator trials estimated the treatment effect of UMEC/VI to 
be 92.17 (maximum likelihood; 95 % confidence interval: 
61.52, 122.82; Fig. 2a) [13, 14].
Table 1 Resource use costs estimated using NHS reference costs for 2011–2012
ER emergency room, COPD chronic obstructive pulmonary disease, ICU intensive care unit, NHS National Health Service
Resource use Costs Source
Cost per day in ICU £1190.29 NHS National Schedule of Reference Costs 2013–2014
Cost per day in general ward £514.00 NHS National Schedule of Reference Costs 2013–2014
Per hospitalisation (COPD Related) £1897.00 NHS National Schedule of Reference Costs 2013–2014
ER visit £123.74 NHS National Schedule of Reference Costs 2013–2014
Hospital outpatient visit £150.00 NHS National Schedule of Reference Costs 2013–2014
Physician visits Cost (2012£)
Daytime home visit £114.00 Personal Social Service Research Unit—Unit Costs of Health and Social Care 2012
Night-time home visit £114.00 Assumed the same as daytime visit
Visit to physician’s office £67.00 Personal Social Service Research Unit—Unit Costs of Health and Social Care 2012
Table 2 Model baseline population parameters
BMI body mass index, CVD cardiovascular disease, ECLIPSE Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints, FEV1%p forced expiratory 
volume in 1 s percent predicted, mMRC modified Medical Research Council dyspnoea scale, PSA probabilistic sensitivity analysis, SE standard error, SGRQ St. George’s 
Respiratory Questionnaire
a SE Calculated or assumed based on availability of data
Parameter Values and  % of patients Standard errora Distributions used in the PSA
Gender
 Female (%) 32.0 % 1.15 % Beta
 Mean age (years) 63.3 0.1 Normal
BMI
 Low (%) 10.4 % 0.84 % Beta
 Medium (%) 65.1 % – –
 High (%) 24.5 % 1.02 % Beta
Any CVD comorbidity (%) 43.5 % 1.13 % Beta
Without comorbidity (%) 56.5 % – –
Any other comorbidity (%) 77.3 % 1.07 % Beta
History of exacerbation, 1 or more (%) 46.2 % 1.21 % Beta
mMRC score ≥2 (%) 100.0 % –
Current smokers (%) 49.0 % 1.16 % Beta
Height (cm) 169.0 0.1 Normal
Fibrinogen (µg/mL) 458.8 102.4 Gamma
Number of exacerbations in prior year 0.50 0.01 Gamma
Proportion of prior exacerbations that are severe 20.0 Gamma
Starting SGRQ score 49.1 0.5 Normal
Starting FEV1 %p (%) 47.7 % 0.2 % Beta
6-min walk distance (m) 378.3 2.9 Normal
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Model predictions
In the base case, UMEC/VI resulted in 5.35 moderate 
exacerbations and 4.32 severe exacerbations per patient 
over patient lifetime. The corresponding predictions for 
tiotropium were 5.35 and 4.30, respectively. The FEV1 
benefit of UMEC/VI resulted in an estimated annual 
exacerbation reduction of 0.04 exacerbations per patient. 
UMEC/VI also resulted in 0.36 incremental life years and 
0.18 incremental QALYs compared with tiotropium over 
patient lifetime (Table 3).
In the base case, the treatment and resource use costs 
were broadly comparable between the two treatment 
alternatives. Per-patient costs over patient lifetime were 
£372.29 more for UMEC/VI compared to tiotropium. The 
resultant incremental cost-effectiveness ratio (ICER) was 
£2087.60 per QALY. This ICER increased to £3856.87/
QALY and £17,540.98/QALY with increase in UMEC/
VI price to £36.85 (10  % premium to tiotropium) and 
£62.76 (equivalent to price of indacaterol plus tiotropium 
in separate inhalers), respectively. At a willingness to pay 
of £20,000 per QALY, the probability of UMEC/VI being 
cost-effective was 84.9  %. This changed to 72.9  % and 
22.9 % as the price of UMEC/VI increased to £36.85 and 
£62.76, respectively (Fig. 2b).
Reducing the model timeframe to 1 year (Scenario A) 
and 5  years (Scenario B) resulted in improvements in 
ICER for UMEC/VI. In Scenario A, UMEC/VI resulted 
in 0.04 fewer exacerbations and 0.01 incremental QALYs 
compared to tiotropium. UMEC/VI also resulted in 
lower annual treatment cost of £0.89, thereby dominat-
ing tiotropium. In Scenario B, UMEC/VI predicted 0.04 
fewer exacerbations per year, 0.04 incremental QALYs, 
and an ICER of £567.04 per QALY. UMEC/VI in Sce-
nario C, which assumed treatment benefit for a period 
of 12 months from treatment initiation, resulted in 0.01 
fewer exacerbations, 0.01 incremental QALYs and £3.67 
lower costs resulting in UMEC/VI dominating tiotro-
pium. At a willingness to pay threshold of £20,000 per 
QALY, the probability of UMEC/VI being cost-effective 
was 93.1, 93.0 and 90.0 % for Scenarios A, Scenario B and 
Scenario C, respectively.
Discussion
Economic assessments in COPD have demonstrated 
combination therapies to be cost-effective in the past, but 
the results have often been inconsistent and depend on 
the choice of products in the combination and the com-
parators. Friedman et  al. reported that the combination 
of albuterol and ipratropium is associated with lower 
rates of exacerbations and is more cost-effective than 
either drug as monotherapy [27]. Similarly, fluticasone 
and salmeterol combination therapy was found to be 
cost-effective in comparison to ipratropium alone [28], 
ipratropium/albuterol (IPA), and tiotropium alone [29]. 
However, the combination of tiotropium and salmeterol 
was not an economically attractive alternative to tiotro-
pium monotherapy [30]. Therefore, it was important to 
assess the cost-effectiveness of UMEC/VI, a new combi-
nation bronchodilator compared with tiotropium, which 
is the current standard of care in symptomatic COPD 
patients.
UMEC/VI has been shown to be an efficacious treat-
ment compared with tiotropium [13, 14]. This study 
assessed the cost-effectiveness of UMEC/VI versus tio-
tropium monotherapy by using a treatment-specific 
COPD economic model. The model was based on robust 
long-term multicentre studies in COPD such as the 
ECLIPSE [19] and Towards a Revolution in COPD Health 
(TORCH) [31] and was further validated using Under-
standing Potential Long-term Impacts on Function with 
Tiotropium (UPLIFT) study results [32]. In addition, 
extensive internal and external validation was undertaken 
Fig. 2 a Random-effects meta-analysis of tiotropium comparator 
trials. b Probabilistic sensitivity analysis: net benefit acceptability 
curves for UMEC/VI compared with tiotropium. CI confidence interval, 
ES effect size, IND indacaterol, TIO tiotropium, UMEC/VI umeclidinium 
bromide/vilanterol. DB2113374 and DB2113360 [11]; ZEP117115 [12]. 
a Effect size (ES) represents increment in FEV1 (ml) of UMEC/VI com-
pared to tiotropium. b Each line on the graph represents probability 
of acceptance of UMEC/VI compared to tiotropium under a particular 
scenario at multiple thresholds of willingness to pay
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to assess its suitability to COPD patient populations likely 
to receive a combination bronchodilator such as UMEC/
VI in clinical practice. Overall, the model demonstrated 
acceptable content and predictive validity.
The model framework allowed FEV1 benefit observed 
in the clinical trial programme for UMEC/VI to predict 
long-term outcomes such as exacerbations, mortality and 
health status. Results suggested small improvements in 
exacerbation rates and QALYs for UMEC/VI compared 
with tiotropium. This is not surprising when consider-
ing that the patient cohort had low risk of exacerbations 
with moderate disease severity and dyspnoea. This cou-
pled with low to medium correlation between FEV1 and 
patient-reported outcomes may not have allowed treat-
ment effect to be completely translated into patient-
reported outcomes. The model allows treatment effect 
to be applied based on SGRQ and to test this hypothesis 
we used results from one of the UMEC/VI studies where 
UMEC/VI demonstrated significant benefit compared 
with tiotropium [14]. The model predicted higher QALY 
benefit (0.35 vs 0.18) and, therefore, more favourable 
outcome for UMEC/VI when treatment effect on SGRQ 
was used instead of FEV1. However, we did not use these 
results in our base case as SGRQ was not the primary end-
point in UMEC/VI clinical studies and UMEC/VI benefit 
over tiotropium was not always significant [13, 14].
A key assumption in the model was the duration of the 
treatment effect. In the base case, we assumed the treat-
ment effect to continue over the lifetime of the patient. 
This is in line with the other published COPD models 
in literature [33]. A scenario analysis assuming a shorter 
duration of treatment effect of 12 months was also per-
formed. This choice of duration was based on UMEC/
VI safety study [23], which demonstrated the benefit of 
UMEC/VI on lung function up to 12 months after treat-
ment initiation. Results showed that UMEC/VI ICER 
improved with a shorter treatment effect than when the 
treatment effect lasted over patient lifetime. This coun-
terintuitive finding may be a result of patients in UMEC/
VI treatment arm living longer and, thereby, incurring 
higher costs later in their life.
Limitations
COPD is a chronic progressive condition, and patients 
with COPD frequently undergo treatment switches or 
escalations. In the current analysis, we did not consider 
any treatment changes. A combination therapy such as 
UMEC/VI is a new class of combination bronchodilators 
currently being introduced, and its impact on the treat-
ment pathway is yet unknown. In addition, we assumed 
that any changes to patient therapy will be similar in 
UMEC/VI and tiotropium treatment arms such that 
there will be no additional benefit of UMEC/VI in delay-
ing treatment escalation. We believe that this is a con-
servative assumption and unlikely to significantly impact 
final conclusions.
Conclusion
Overall, UMEC/VI can be considered a cost-effective 
alternative to tiotropium. Further evidence on UMEC/
VI is needed to assess its long-term benefit for COPD 
patients. Along with other dual bronchodilators, this 
may provide additional options in the armamentarium to 
physicians for COPD patients in need of bronchodilator 
treatment.
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